Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

3

Revenue 2014

Roche

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Roche's 2013 sales performance.

Merck's anacetrapib rescued by positive phase III trial

Merck's anacetrapib rescued by positive phase III trial

Optimism for the CETP inhibitor had pretty much evaporated after three other drugs in the class - Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - failed to show a

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara

Sanofi and Regeneron bag EU approval for arthritis drug Kevzara It will compete in the EU rheumatoid arthritis market with Roche's $1.7bn IL-6 inhibitor Actemra (tocilizumab), as well as older TNF-blocker drugs including the world's biggest

Warning sounded on pharma's long-term sales prospects

Warning sounded on pharma's long-term sales prospects As it stands Novartis, Pfizer and Roche are competing head to head for the crown of being the largest company by worldwide prescription sales in 2022, with Novartis seeming to have

Medmeme appoints Dr Joseph Laudano to medical affairs role

Medmeme appoints Dr Joseph Laudano to medical affairs role Laudano has also held positions for Forest Research Institute as senior director of medical affairs and Roche Laboratories in various medical affairs and marketing positions.

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations NICE relents on Kadcyla after Roche pricing negotiations. HER2-positive breast cancer therapy to be made available on the NHS in England. ... Roche has offered an undisclosed price cut which means that around 1, 200 women with incurable secondary breast

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Roche
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
Immunology revenue 2014
1: AbbVie
2: Johnson & Johnson
3: Pfizer
4: Amgen
5: Merck & Co.
6: Astellas
7: Roche
8: Novartis
9: Bristol-Myers Squibb
10: Mitsubishi Tanabe
11: UCB
12: Hisamitsu
13: Daiichi Sankyo
14: Takeda
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Biologic revenue 2014
1: Roche
2: Amgen
3: Novo Nordisk
4: AbbVie
5: Sanofi
6: Johnson & Johnson
7: Pfizer
8: Merck & Co.
9: Lilly
10: Biogen Idec
11: Merck KGaA
12: GlaxoSmithKline
13: Bristol-Myers Squibb
14: Novartis
15: Bayer

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Devil_in_the_edetail.png
The Devil is in the E-Detail
All too often, pharma companies are relying on the e-detailing approach, and missing a big opportunity to engage with their customers, build relationships, and add value....
Medical Translations: Why you need to get it right the first time
British and American senior medical executives admit to image and reputation being at risk because of misinterpreted cultural references or linguistic errors....
Digital disruption
How pharma is keeping up with the pace of change...

Infographics